Drug information of Tavaborole

Tavaborole

Drug group:

Brand drugs:Kerydin

Tavaborole topical is used to treat a fungal infection of the toenail called onychomycosis

Drug forms
  • Tavaborole

Mechanism of effect

An oxaborole antifungal (boron-containing compound); inhibits protein synthesis by inhibition of an aminoacyl-transfer ribonucleic acid (tRNA) synthetase (AARS)

Pharmacokinetics

Metabolism:Extensive. Metabolite profiling revealed trace levels of a sulfated-conjugate and a benzoic acid metabolite, consistent with the known biotransformation of tavaborole

Excretion:Urine

Half life: 28.5 hr

Drug indications

Onychomycosis of the Toenail

Dosage

Apply to affected toenails qDay for 48 weeks

Drug contraindications

None reported by manufacturer

Side effects

Hypersensitivity , Peeling

Application site exfoliation

Ingrown toenail

Application site erythema

Application site dermatitis

Hypersensitivity, contact allergy

Interactions

There are no known significant interactions.

Alerts

- Not for oral, ophthalmic, or intravaginal use

- Product is flammable; avoid use near heat or open flame

- Persistent local irritation, erythema, exfoliation, or dermatitis may develop

-  Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution

Points of recommendation

- Clean and dry nails prior to use; apply to completely cover nail surface and under tip of each nail being treated; allow solution to dry following application

- Avoid contact with eyes, mouth, vagina, or skin immediately surrounding treated nail; wipe away excess solution from surrounding skin

Pregnancy level

Consult a physician before using

Animal studies have revealed evidence of embryofetal mortality and toxicity and skeletal malformations at oral doses causing maternal toxicity.There are no available data on use in pregnant women to inform a drug associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes.This drug should be used during pregnancy only if the benefit outweighs the risk.

Breast feeding warning

There is no information available on presence in human milk, effects on breastfed infant or on milk production in women who are breastfeeding; drug is systemically absorbed

Related drugs

Ciclopirox , Butenafine


Ask a Pharmacist


User's questions
    No comments yet.